Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
FDA approves at-home use of BioXcel's agitation drug Igalmi
00

FDA approves at-home use of BioXcel's agitation drug Igalmi

Nov 16, 2026

The U.S. Food and Drug Administration approved at-home, unsupervised outpatient use of BioXcel Therapeutics' sublingual film drug Igalmi (dexmedetomidine) on November 16, 2026. Initially approved in April 2022 for supervised settings, Igalmi fills a gap in outpatient treatment for agitation affecting 25% to 40% of schizophrenia and bipolar disorder patients. Teva Pharmaceuticals acquired the drug's assets in October 2026 and plans to announce commercialization strategy at a later date.

FDA approval and asset acquisition

  • ▪The FDA approved at-home, unsupervised outpatient use of BioXcel Therapeutics' sublingual film drug Igalmi
  • ▪BioXcel Therapeutics completed the sale of nearly all its assets, including Igalmi, to a unit of Israel-based Teva Pharmaceuticals last month
  • ▪Igalmi, chemically known as dexmedetomidine, was originally approved by the FDA as an orally dissolving film in April 2022 for medically supervised use in adults

Commercial plans and market need

  • ▪Teva Pharmaceuticals stated that it will announce commercialization plans for the at-home outpatient use of Igalmi at a later date
  • ▪Teva Pharmaceuticals stated that no prior FDA-approved options were available for treating agitation associated with schizophrenia or bipolar disorder in unsupervised outpatient settings

Drug mechanism and Therapeutic goals

  • ▪Pharmacologic treatments for agitation aim to provide rapid symptom control while preserving patient safety without continuous inpatient supervision
  • ▪Teva said Igalmi targets brain receptors that help reduce stress-related behaviors such as agitation in patients with neurological disorders

Agitation and underlying mental health disorders

  • ▪Agitation affects between 25% and 40% of patients diagnosed with schizophrenia or bipolar disorder, according to statements by Teva Pharmaceuticals
  • ▪Schizophrenia causes delusions, hallucinations, and disorganized thinking, while bipolar disorder causes severe mood swings

2 sources

Medscape
US FDA Approves At-home Use Of BioXcel's Agitation Drug
View source article
Reuters
US FDA approves at-home use of BioXcel's agitation drug | Reuters
View source article

Story comments

Loading comments…

Related entities

Bipolar disorderIsraelSchizophrenia

Topics

FDA drug approvalMental Health & WellbeingDrug Policy, Pricing & ApprovalPsychosis & schizophrenia spectrum